PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go:
Extended
investment:
Withheld
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go:
TBC
investment:
Withheld
Milbotix, a healthtech start-up, supported by the Alzheimer's Society and the UK Dementia Research Institute, is driven by its innovative product SmartSocks™. This wearable technology aims to assist individuals with dementia facing communication challenges and their caregivers. Globally, the number of people with dementia is increasing significantly, reaching 78 million by 2030 and 139 million by 2050. Half of those diagnosed with dementia encounter challenging behavioral symptoms due to distress. Early distress management not only enhances well-being but also helps prevent escalating behavioral issues. SmartSocks™ utilize sensors and artificial intelligence to notify dementia caregivers about early signs of pain and anxiety in their patients.
days to go:
Expired
investment:
£220,780
Fiinu are building a new digital bank. They intend to distrupt the financial services industry, whilst helping customers improve their lives through better banking and a people before profit ethos. Their goal is for customers to be in better financial shape after they join Fiinu. Fiinu is currently undergoing the Bank of England authorisation.
days to go:
Expired
investment:
£563,099
Cyclr is a cloud-based software that allows the user to connect the apps that they already run their business on. This makes it simple to synchronise data with another system.
days to go:
Expired
investment:
£100,490
Ziglu is a financial technology entity that allows a user to access both Forex and digital currencies seamlessly. The company permits a user to use any currency via its Mastercard debit card and protects the user's digital currency up to £50,000 against cyber-attacks. Ziglu is authorised by the UK's Financial Conduct Authority (FCA) as an Electronic Money Institution (EMI) and is one of the first companies involved with digital currencies to be registered under the UK’s Anti-Money Laundering Regulations (AMLR). The company has achieved a 94% rating on TrustPilot, offers customers the option to send money via cryptocurrency, and previously raised £5.25 million in seed funding. Ziglu has featured in media entities like Coindesk and Yahoo Finance. It will use 30% of the investment in product development, 60% on user acquisition, and 10% on international expansion initiatives.
days to go:
Expired
investment:
£3,041,878
